Free Trial

Celldex Therapeutics (CLDX) SEC Filings & 10K Form

$44.56
+0.70 (+1.60%)
(As of 07/26/2024 ET)

Recent Celldex Therapeutics SEC Filings

DateFilerForm TypeView
06/14/2024
4:34 PM
Celldex Therapeutics (Subject)
Crowley Elizabeth (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/14/2024
4:12 PM
Celldex Therapeutics (Subject)
Martin Samuel Bates (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/14/2024
7:00 AM
Celldex Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/13/2024
3:05 PM
Celldex Therapeutics (Issuer)
Young Diane C. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2024
4:23 PM
Celldex Therapeutics (Subject)
Young Diane C. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/03/2024
4:51 PM
Celldex Therapeutics (Subject)
Jimenez Freddy A. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/03/2024
4:14 PM
Celldex Therapeutics (Subject)
Wright Richard M. (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/30/2024
5:01 PM
Celldex Therapeutics (Subject)
Martin Samuel Bates (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/30/2024
5:05 PM
Cavanaugh Sarah (Reporting)
Celldex Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/30/2024
4:47 PM
Celldex Therapeutics (Subject)
Crowley Elizabeth (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/30/2024
2:20 PM
Celldex Therapeutics (Subject)
Heath-Chiozzi Margo (Reporting)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/25/2024
7:00 AM
Celldex Therapeutics (Filer)
Form DEF 14A
02/26/2024
7:18 AM
Celldex Therapeutics (Filer)
Form 424B5
02/26/2024
6:05 AM
Celldex Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/26/2024
6:01 AM
Celldex Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2024
11:52 AM
Celldex Therapeutics (Subject)
Kynam Capital Management, LP (Filed by)
Form SC 13G
02/14/2024
10:48 AM
Celldex Therapeutics (Subject)
EVENTIDE ASSET MANAGEMENT, LLC (Filed by)
Form SC 13G
02/14/2024
6:38 AM
Celldex Therapeutics (Subject)
RTW INVESTMENTS, LP (Filed by)
Form SC 13G/A
02/13/2024
8:41 AM
Celldex Therapeutics (Subject)
Polar Capital Holdings Plc (Filed by)
Form SC 13G
02/09/2024
7:50 AM
Celldex Therapeutics (Subject)
FMR LLC (Filed by)
Form SC 13G/A
01/04/2024
3:05 PM
Celldex Therapeutics (Issuer)
Martin Samuel Bates (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2023
3:15 PM
Celldex Therapeutics (Subject)
Point72 Asset Management, L.P. (Filed by)
Form SC 13G
11/08/2023
4:03 PM
Celldex Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/06/2023
8:00 AM
Celldex Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools

This page (NASDAQ:CLDX) was last updated on 7/27/2024 by MarketBeat.com Staff

From Our Partners